ALNY News and Press, Alnylam Pharmaceuticals Inc. From 01/05/23

Alnylam Pharmaceuticals ( NASDAQ: ALNY ) on Thursday said lead independent director Amy Schulman will assume the role of chair of the board from Michael Bonney. Bonney will continue on the board as a non-independent director. Bonney had been serving an interim role ...

– Appoints Carolyn Bertozzi, Ph.D., Nobel Laureate and Leading Voice for Chemical Biology, Emerging Technology, and Life Sciences Companies – – Michael W. Bonney Steps Down as Executive Chair and Continues on Board as Non-Independent Director – ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:45 am PT (12:45 pm ...

Alnylam Pharma ( NASDAQ: ALNY ) said on Wednesday it had submitted an application to begin trial of ALN-KHK, an investigational RNAi therapy targeting ketohexokinase to treat Type 2 diabetes mellitus (T2DM) to Health Canada. The company plans to begin enrollment in a Phase 1/...

– Company Expects to Initiate a Phase 1/2 Study for ALN-KHK in Early 2023, with Initial Results Expected in Late 2023 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi (RNA interference) therapeutics company, announced today that the Comp...

− Product and Pipeline Goals Detail Execution across Four Commercial Brands, Including One Potential Label Expansion, and Ten Clinical Data Readouts From Proprietary and Partner Programs – − Pipeline Programs and Scientific Innovation Highlighted at R&D Day Ex...

– sNDA Submission is Based on Findings from the APOLLO-B Phase 3 Study That Showed Patisiran Demonstrated Significant Improvement on Functional Capacity, Health Status and Quality of Life Compared to Placebo at Month 12 – – Study Also Demonstrated Encouraging Safety P...

- Recognition Marks Alnylam’s Eighth Year in a Row on this Prestigious List, and the Second Consecutive Year Ranking #1 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its first-place ranking in Boston Globe’s 2022 ...

Summary Recent clinical successes and M&A could bring interest back to biotechnology, especially among mid-capitalization names with derisked or approved products. Restructuring, corporate activity, and COVID-19 revenues have significantly improved the funding positions of man...

Summary Alnylam's third quarter results were basically on target, with a stronger Amvuttra launch leading to more Onpattro switchovers, and some weakness in Givlaari and Oxlumo. There are still multiple credible and significant questions about whether Onpattro data will support wi...